PER
Click for more information
2.44% 8.0¢ percheron therapeutics limited

AkkiThere you go againTeva made a huge mistake giving Atl 1102...

  1. itsagas
    13,162 Posts.
    lightbulb Created with Sketch. 1383
    clock Created with Sketch.
    03/09/23
    19:10
    Post #: 69710768
    Akki
    There you go again
    Teva made a huge mistake giving Atl 1102 back
    Teva then backed another drug which failed.
    Tox study Re done and proved successful…by Anp
    There has been no drugs to match ATL1102 for MS
    The FDA limited ATL1102 to 25 mg
    No Pharma would touch ATL1102 without Tox study Re 12 months .
    Now new technology Re MRI proves Atl 1102 results were better than thought
    Akki please take

    ANP Price at posting: 5.9¢ Sentiment: None Disclosure: Held
    Likes Created with Sketch. 6  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

G88 Golden Mile ditches Marble Bar and Murchison tenements after weak fieldwork results
right-arrow Created with Sketch.
NEWS Appliances and furnishings impress - will Harvey Norman be next?
right-arrow Created with Sketch.
NEWS Unchanged wage growth in June quarter, but public sector leaps ahead
right-arrow Created with Sketch.
NEWS Was last week's panic justified?
right-arrow Created with Sketch.
MKG Mako reports shallow high grade gold in scout drilling at Tchaga North
right-arrow Created with Sketch.
MOV MOVE Logistics picks new interim CEO to take over operations from early September
right-arrow Created with Sketch.
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
8.0¢ 		Change
-0.002(2.44%) 		Mkt cap ! $72.12M
Open High Low Value Volume
8.3¢ 8.4¢ 8.0¢ $58.49K 703.3K

Buyers (Bids)

No. Vol. Price($)
2 127624 8.0¢
 

Sellers (Offers)

Price($) Vol. No.
8.4¢ 25545 1
View Market Depth
Last trade - 16.10pm 16/08/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.